Zydus Lifesciences gains USFDA approval for prostate cancer drug

Zydus Lifesciences Ltd has received approval from the US Food and Drug Administration (USFDA) to manufacture a generic version of a prostate cancer treatment drug. The drug is called Apalutamide, and the approved tablets will be 60 mg each. The company announced this approval on Tuesday. The manufacturing will take place at Zydus's facility located in Ahmedabad, India. Apalutamide is used to treat metastatic castration-sensitive prostate cancer. This drug is an androgen receptor inhibitor. It has seen significant sales in the United States, reaching about $1.1 billion annually, according to recent data. Zydus Lifesciences is now set to contribute to the market with their generic version of the medication.